(E)-3-(4-(neopentyloxy)-7H-pyrrolo[2,3-d]pyrimidin-5-yl)acrylamide

ID: ALA3919781

Chembl Id: CHEMBL3919781

PubChem CID: 73051906

Max Phase: Preclinical

Molecular Formula: C14H18N4O2

Molecular Weight: 274.32

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(C)(C)COc1ncnc2[nH]cc(/C=C/C(N)=O)c12

Standard InChI:  InChI=1S/C14H18N4O2/c1-14(2,3)7-20-13-11-9(4-5-10(15)19)6-16-12(11)17-8-18-13/h4-6,8H,7H2,1-3H3,(H2,15,19)(H,16,17,18)/b5-4+

Standard InChI Key:  FVFLNMVKWNRXOS-SNAWJCMRSA-N

Associated Targets(Human)

TAB1 Tchem TAK1/TAB1 (257 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MAP3K7 Tchem Mitogen-activated protein kinase kinase kinase 7 (1167 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TAB1 Tchem Mitogen-activated protein kinase kinase kinase 7-interacting protein 1 (47 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 274.32Molecular Weight (Monoisotopic): 274.1430AlogP: 1.88#Rotatable Bonds: 4
Polar Surface Area: 93.89Molecular Species: NEUTRALHBA: 4HBD: 2
#RO5 Violations: HBA (Lipinski): 6HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 12.68CX Basic pKa: 5.03CX LogP: 1.93CX LogD: 1.93
Aromatic Rings: 2Heavy Atoms: 20QED Weighted: 0.83Np Likeness Score: -0.52

References

1.  (2014)  4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment, 
2.  (2016)  4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment,